INFLARX N.V.
INFLARX N.V.
Aktie · NL0012661870 · IFRX · A2H7A5 (XNAS)
Übersicht Finanzkennzahlen
0,83 USD
1,17 % 0,010 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 23:29

Aktuelle Kurse von INFLARX N.V.

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
IFRX
USD
06.06.2025 23:29
0,83 USD
0,83 USD
-0,12 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 5,21 % -47,63 % -30,83 % -68,07 % -48,44 % -88,92 %
Asset Allocation
VermögenswertAnteil %
Stock non-US49,50 %
Stock US49,12 %
Cash1,38 %
NotClassified0,00 %
Other0,00 %
Bond0,00 %
Die größten Positionen
SymbolISINNameAnteil %
CRLCharles River Laboratories International Inc 6,62 %
TPLTexas Pacific Land Corporation 5,65 %
FNVFranco-Nevada Corporation 4,85 %
PSKPrairieSky Royalty Ltd 4,63 %
DB1Deutsche Börse AG 4,45 %
ASXASX Limited 4,41 %
ICEIntercontinental Exchange Inc 4,25 %
WPMWheaton Precious Metals Corp 4,08 %
ADMArcher-Daniels-Midland Company 3,93 %
MMCMarsh & McLennan Companies Inc 3,43 %
Regionen Verteilung
RegionAnteil %
North America81,33 %
Europe Developed7,36 %
Australasia5,98 %
Asia Developed4,25 %
Japan1,08 %
Africa/Middle East0,00 %
Asia Emerging0,00 %
Europe Emerging0,00 %
Latin America0,00 %
United Kingdom0,00 %
Sektor Verteilung
SektorAnteil %
Finanzdienstleistungen33,23 %
Grundstoffe22,05 %
Energie18,96 %
Gesundheitswesen8,10 %
Immobilien7,47 %
Basiskonsumgüter5,46 %
Industrieunternehmen2,44 %
Technologie2,30 %
Verbrauchsgüter0,00 %
Telekommunikation0,00 %

Firmenprofil zu INFLARX N.V. Aktie

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Fonds Stammdaten
Emittent Horizon Kinetics
Wertpapierart ETF
Name Horizon Kinetics Inflation Beneficiaries ETF
Fondswährung USD
Kategorie World Large-Stock Growth
fund.
Fonds Kennzahlen
Fondgröße 631.168,26 EUR
Anlagestrategie
The investment seeks long-term growth of capital in real (inflation-adjusted) terms. The fund is an actively-managed ETF that seeks to achieve its investment objective by investing primarily in the equity securities of domestic and foreign companies that are expected to benefit, either directly or indirectly, from rising prices (inflation). The fund's investments in equity securities are generally expected to include common stock, ownership units of publicly traded MLPs, and units of royalty trusts. The fund is non-diversified.

Unternehmensdaten

Name INFLARX N.V.
Firma InflaRx N.V.
Symbol IFRX
Website https://www.inflarx.de
Heimatbörse XNAS NASDAQ
WKN A2H7A5
ISIN NL0012661870
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Niels C. Riedemann M.D., Ph.D.
Marktkapitalisierung 70 Mio
Land Deutschland
Währung USD
Mitarbeiter 0,1 T
Adresse Winzerlaer Str. 2, 07745 Jena
IPO Datum 2017-11-07

Ticker Symbole

Name Symbol
Frankfurt IF0.F
NASDAQ IFRX

Weitere Aktien

Investoren die INFLARX N.V. die halten, haben auch folgende Aktien im Depot:
ATLANTIC SAPPHIRE NK 10
ATLANTIC SAPPHIRE NK 10 Aktie
BAIDU INC - ADR
BAIDU INC - ADR Aktie
BIONTECH SE ADR
BIONTECH SE ADR Aktie
BONESUPPORT HOLDING AB
BONESUPPORT HOLDING AB Aktie
BYD
BYD Aktie
DEUTSCHE TELEKOM AG
DEUTSCHE TELEKOM AG Aktie
GAZPROM ADR
GAZPROM ADR Hinterlegungsschein
JD.CO INC - ADR
JD.CO INC - ADR Aktie
LYXOR MSCI EUROPE (DR) UCITS ETF - ACC
LYXOR MSCI EUROPE (DR) UCITS ETF - ACC ETF
META PLATFORMS INC
META PLATFORMS INC Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
RIO TINTO
RIO TINTO Aktie
VA-Q-TEC AG
VA-Q-TEC AG Aktie
WEICHAI POWER CO
WEICHAI POWER CO Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025